Skip Navigation Links

Bookmark and Share
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for [18F]-APN-1607 Tau PET Imaging Tracer for Dementia
SUZHOU, China, Oct. 28, 2020 /PRNewswire/ -- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's ...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.